Overview

A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)

Status:
Terminated
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This study will be used to determine the maximum tolerated dose of oral clofarabine when administered daily for 14 consecutive days repeated every 21 days.
Phase:
Phase 1
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Clofarabine